(e voe LOK ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Auto-injector, Subcutaneous [preservative free]:
Repatha SureClick: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]
Solution Cartridge, Subcutaneous [preservative free]:
Repatha Pushtronex System: 420 mg/3.5 mL (3.5 mL) [contains polysorbate 80]
Solution Prefilled Syringe, Subcutaneous [preservative free]:
Repatha: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]
Brand Names: U.S.
- Repatha Pushtronex System
- Repatha SureClick
- Antilipemic Agent, PCSK9 Inhibitor
- Monoclonal Antibody
Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL; therefore, the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-cholesterol (LDL-C). By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.
IV: Vd: ~3.3 L
Onset of Action
Peak effect: Proprotein convertase subtilisin kexin type 9 (PCSK9) suppression: 4 hours
Time to Peak
SubQ: 3 to 4 days
11 to 17 days
Special Populations: Hepatic Function Impairment
In patients with mild or moderate hepatic impairment, a 20% to 30% lower mean Cmax and 40% to 50% lower mean AUC occurs.
Use: Labeled Indications
Hyperlipidemia, primary: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C).
Homozygous familial hypercholesterolemia: Adjunct to diet and other LDL-lowering therapies (eg, statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
Off Label Uses
Atherosclerotic cardiovascular disease, high CV risk
Data from a large, randomized, double-blind, placebo-controlled cardiovascular outcomes study (the FOURIER trial) in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) supports the use of evolocumab when added to maximally tolerated statin therapy to significantly reduce the risk of non-fatal MI and non-fatal stroke; no reduction in CV mortality or all-cause mortality was seen. Note: Patients enrolled in clinical trial had either a fasting LDL cholesterol ≥70 mg/dL or a non-HDL cholesterol ≥100 mg/dL [Sabatine 2017].
Serious hypersensitivity to evolocumab or any component of the formulation.
Documentation of allergenic cross-reactivity for PCSK9 inhibitors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Hyperlipidemia, primary: SubQ: 140 mg every 2 weeks or 420 mg once monthly
Switching regimens: Administer the first dose of the new regimen on the next scheduled day of the prior regimen.
Homozygous familial hypercholesterolemia: SubQ: 420 mg once monthly.
Off-label dosing: 420 mg once every 2 weeks (after 12 weeks, may decrease to 420 mg once a month) in conjunction with lipid apheresis has been studied in a limited number of patients (Bruckert 2014). The European Atherosclerosis Society recommends administration directly after lipid apheresis (EAS [France 2016]).
Atherosclerotic cardiovascular disease (ASCVD), high CV risk (off-label use): SubQ: 140 mg every 2 weeks or 420 mg once monthly in combination with an optimized regimen of lipid-lowering therapy (eg, high-intensity statin).
Refer to adult dosing.
Homozygous familial hypercholesterolemia: Adolescents 13 to 17 years: SubQ: Refer to adult dosing
Missed doses: Administer as soon as possible if there are more than 7 days until next scheduled dose, or omit the missed dose and administer next dose according to the original schedule.
Dosing: Renal Impairment
Mild to moderate impairment: No dosage adjustment necessary.
Severe impairment (estimated GFR <30 mL/minute/1.73 m2): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment is unlikely to be required as monoclonal antibodies are not known to be renally eliminated.
Dosing: Hepatic Impairment
Mild to moderate impairment (Child Pugh class A and B): No dosage adjustment necessary.
Severe impairment (Child Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Prior to use, if refrigerated, allow to warm to room temperature for at least 30 minutes. Do not warm in any other way.
If refrigerated, allow to stand at room temperature for at least 30 minutes prior to use (do not warm with heat or hot water).
SubQ: Using a single-use prefilled syringe or single-use prefilled autoinjector, administer subcutaneously into areas of the abdomen (except for the 2-inch area around the navel), thigh, or upper arm; only use areas that are not tender, bruised, red, or indurated. Do not coadminister with other injectable drugs at the same injection site. Rotate the injection site with each injection.
To administer the once-monthly dose (ie, 420 mg), may either administer subcutaneously over 9 minutes using the single-use infusor with prefilled cartridge or give 3 separate subcutaneous 140 mg injections consecutively within a 30-minute period using the single-use prefilled autoinjector or single-use prefilled syringe.
Store between 2°C to 8°C (36°F to 46°F) in the original carton. May also be kept at room temperature (at 20°C to 25°C [68°F to 77°F]) in the original carton; however, under these conditions, must use within 30 days (discard if not used within 30 days). Protect from direct light and do not expose to temperatures above 25°C (77°F). Do not freeze. Do not shake.
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. Avoid combination
>10%: Respiratory: Nasopharyngitis (6% to 11%)
1% to 10%:
Cardiovascular: Hypertension (3%)
Central nervous system: Dizziness (4%), fatigue (2%)
Dermatologic: Skin rash (1%)
Gastrointestinal: Gastroenteritis (3% to 6%), nausea (2%)
Genitourinary: Urinary tract infection (5%)
Hematologic & Oncologic: Bruise (1%)
Infection: Influenza (8% to 9%)
Local: Injection site reaction (including erythema, pain, bruising: 6%)
Neuromuscular & Skeletal: Myalgia (4%)
Respiratory: Upper respiratory tract infection (9%), cough (1% to 5%), sinusitis (4%)
<1% (Limited to important or life-threatening): Antibody development, decreased LDL cholesterol (<25 mg/dL), hypersensitivity
Concerns related to adverse effects:
• Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria) have been reported, some requiring discontinuation. Discontinue treatment and initiate supportive treatment in patients who develop signs/symptoms of serious allergic reaction; monitor until symptoms resolve.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Dosage form specific issues:
• Latex: The packaging (needle cap of prefilled syringe and autoinjector) may contain dry natural rubber, which is a derivative of latex.
Lipid profile; in patients with homozygous familial hypercholesterolemia, measure LDL-C levels 4 to 8 weeks after initiation (response to evolocumab will depend on degree of LDL-receptor function); signs/symptoms of hypersensitivity reactions.
Adverse events were not observed in animal reproduction studies. IgG antibodies are known to cross the placenta in increasing amounts during the second and third trimesters; exposure of the fetus to evolocumab is expected.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience pharyngitis, rhinitis, flu-like symptoms, signs of common cold, back pain, or injection site irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about evolocumab
- Side Effects
- During Pregnancy
- Dosage Information
- Support Group
- En Español
- 40 Reviews – Add your own review/rating
- Drug class: PCSK9 inhibitors
Other brands: Repatha